Tiansheng Pharmaceutical Group Co., Ltd. (002872.SZ)
CNY 4.05
(1.0%)
CNY 4.05
(1.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 29.13 Million CNY | -8.84% |
| 2022 | 39.31 Million CNY | -32.29% |
| 2021 | 59.9 Million CNY | 1108.6% |
| 2020 | -370.22 Million CNY | -343.03% |
| 2019 | -82.27 Million CNY | -98.34% |
| 2018 | 187.72 Million CNY | -55.89% |
| 2017 | 427.96 Million CNY | 15.07% |
| 2016 | 397.84 Million CNY | 8.36% |
| 2015 | 302.95 Million CNY | 20.92% |
| 2014 | 264.93 Million CNY | 21.89% |
| 2013 | 239.19 Million CNY | 61.74% |
| 2012 | 158.2 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 14.23 Million CNY | 275.77% |
| 2024 Q1 | -18.69 Million CNY | -69.16% |
| 2024 Q2 | 3.28 Million CNY | -22.47% |
| 2023 Q1 | -13.8 Million CNY | -542.78% |
| 2023 FY | - CNY | -8.84% |
| 2023 Q2 | -26.1 Million CNY | -89.14% |
| 2023 Q3 | -29.56 Million CNY | -13.26% |
| 2023 Q4 | 13.74 Million CNY | 146.49% |
| 2022 Q4 | 3.11 Million CNY | 120.62% |
| 2022 FY | - CNY | -32.29% |
| 2022 Q3 | -15.11 Million CNY | 42.11% |
| 2022 Q2 | -26.11 Million CNY | -99.65% |
| 2022 Q1 | -13.08 Million CNY | -137.28% |
| 2021 Q1 | -16.58 Million CNY | 74.94% |
| 2021 Q4 | 35.08 Million CNY | 232.45% |
| 2021 Q2 | 1.47 Million CNY | 108.89% |
| 2021 FY | - CNY | 1108.6% |
| 2021 Q3 | -26.48 Million CNY | -1896.95% |
| 2020 Q2 | -36.43 Million CNY | -1191.27% |
| 2020 FY | - CNY | -343.03% |
| 2020 Q4 | -66.18 Million CNY | -154.01% |
| 2020 Q3 | -26.05 Million CNY | 28.48% |
| 2020 Q1 | 3.33 Million CNY | 104.6% |
| 2019 Q4 | -72.58 Million CNY | -11.66% |
| 2019 Q3 | -65.01 Million CNY | -789.18% |
| 2019 Q2 | 9.43 Million CNY | -63.07% |
| 2019 Q1 | 25.54 Million CNY | 123.86% |
| 2019 FY | - CNY | -98.34% |
| 2018 Q2 | 56.79 Million CNY | -49.72% |
| 2018 Q3 | 34.21 Million CNY | -39.76% |
| 2018 Q4 | -107.03 Million CNY | -412.89% |
| 2018 FY | - CNY | -55.89% |
| 2018 Q1 | 112.94 Million CNY | 6.39% |
| 2017 Q1 | 534.07 Million CNY | 416.73% |
| 2017 FY | - CNY | 15.07% |
| 2017 Q4 | 106.16 Million CNY | 49.7% |
| 2017 Q3 | 70.91 Million CNY | 118.06% |
| 2017 Q2 | -392.69 Million CNY | -173.53% |
| 2016 Q3 | 68.2 Million CNY | 119.4% |
| 2016 FY | - CNY | 8.36% |
| 2016 Q4 | 103.35 Million CNY | 51.54% |
| 2016 Q2 | -351.5 Million CNY | -171.78% |
| 2016 Q1 | 489.71 Million CNY | 0.0% |
| 2015 FY | - CNY | 20.92% |
| 2014 FY | - CNY | 21.89% |
| 2013 FY | - CNY | 61.74% |
| 2012 FY | - CNY | 0.0% |